India: Novartis fights on in Gleevec battle


Novartis has now appealed to the Supreme Court in a bid to overturn the rejection of its controversial patent for Gleevec. Archana Shanker of Anand and Anand discusses the issues raised by the case

The speculation seemed to have come to an end on June 26 2009 when the Intellectual Property Appellate Board (IPAB) gave its decision on the Novartis patent application directed to the beta crystalline version of imatinib mesylate (Gleevec), refusing the patent application. Novartis then filed a special leave petition (SLP) before the Supreme Court, which has issued notice to the respondents in the matter (Union of India and others) to decide the issue of maintainability.

The facts of the Novartis pre-grant oppositions are well known and this article is only an attempt to summarise the issues and the propositions of law that have been discussed in the judgment.

By way of background, Novartis AG, a Swiss pharmaceutical company, applied for patent number 1602/MAS/1998 claiming Swiss priority of July 18 1997 for an invention directed to a "beta crystalline form of imatinib mesylate". Cancer Patient Aid Association (CPAA), NATCO Pharma, CIPLA...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Join us on Tuesday for a Twitter Q&A with @theIPO's @RMW136 on innovation and IP 4pmBST/11amEST. Any questions you want to ask her? #MIP50

Sep 19 2014 11:21 ·  reply ·  retweet ·  favourite
ManagingIP profile

Three new patent attorney partners for @finneganIPLaw in London - details http://t.co/bfciijxZUU

Sep 18 2014 01:52 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @OliviaLuk1: @ManagingIP can't do it but that sounds awesome for a younger professional!

Sep 18 2014 01:46 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


AIPPI Congress News 2014

Read this year's AIPPI Congress News - published daily by Managing IP direct from the AIPPI Annual Meeting in Toronto
null null null

September 2014

The surprising rise of the PTAB

Patent owners have been shocked at how popular IPR proceedings at the PTAB have proven. As the USPTO mulls over changes and the Federal Circuit braces itself for a deluge of appeals, Michael Loney reports on how the PTAB is likely to evolve



Most read articles

Supplements